Standard Administration for Psoriatic Arthritis
Cosentyx (secukinumab) is administered by subcutaneous injection for psoriatic arthritis in adults. The typical starting dose is 150 mg once weekly for the first 5 weeks (weeks 0, 1, 2, 3, and 4), followed by 150 mg every 4 weeks. Some patients may need 300 mg (two 150 mg injections) at each dose for better response, especially if they have co-existing moderate-to-severe plaque psoriasis.[1]
Available Formulations and Devices
It comes as a 150 mg/mL prefilled syringe or autoinjector (SensoReady pen). Injections go into the thigh, abdomen (at least 2 inches from the navel), or upper arm (with help). Rotate sites to avoid irritation. No shaking required—gently tap to check for air bubbles.[1]
Self-Administration Steps
- Wash hands and clean injection site with alcohol swab.
- Let device warm to room temperature (30-45 minutes out of fridge).
- Remove cap, pinch skin, insert needle at 45-90 degree angle.
- Press plunger or button fully until empty (may hear a click).
- Hold 5-30 seconds post-injection, then safely discard in sharps container.
Full instructions and videos are in the prescribing information or patient app.[1]
Dosing Adjustments and Missed Doses
No adjustments for mild kidney/liver issues. If a dose is missed, inject as soon as possible, then resume schedule—don't double up. Doctors may tweak based on response or infections.[1]
How It Compares to Other PsA Biologics
Unlike TNF inhibitors (e.g., Humira, weekly or biweekly shots), Cosentyx targets IL-17A with less frequent maintenance dosing. Etanercept (Enbrel) is twice weekly initially. IL-23 inhibitors like Tremfya are monthly after loading.[2]
Common Injection Site Reactions
Redness, itching, or pain at site affects about 15-20% of patients, usually mild and short-lived. Rare serious reactions include infections—monitor and report persistent issues.[1][3]
Storage and Travel Tips
Refrigerate at 36-46°F; don't freeze. Unopened pens stable at room temp up to 90°F for 30 days. For travel, use cooler packs.[1]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: American College of Rheumatology PsA Guidelines
[3]: FDA Label for Secukinumab